• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ardelyx Inc.

    11/5/24 4:47:54 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email
    S-8 1 tm2427403d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 5, 2024

     

    Registration No. 333-                 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    A black text on a white background

Description automatically generated

    ARDELYX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-36485 26-1303944
    (State or other jurisdiction
    of incorporation  or organization)
    (Commission
    File Number)
    (IRS Employer
    Identification Number)

     

    400 Fifth Ave., Suite 210

    Waltham, Massachusetts

    02451
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (510) 745-1700

     

    Amended and Restated 2014 Equity Incentive Award Plan

    Amended and Restated 2014 Employee Stock Purchase Plan

    (Full Title of the Plans)

     

    Elizabeth Grammer

    Chief Legal and Administrative Officer

    Ardelyx, Inc.

    400 Fifth Avenue, Suite 210

    Waltham, MA 02451

    (510) 745-1700

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mark V. Roeder, Esq.

    John C. Williams, Esq.

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer ¨
    Non-accelerated filer ¨   Smaller reporting company ¨
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

    This registration statement will become effective upon filing in accordance with Rule 462 under the Securities Act. Proposed sale to take place as soon after the effective date of the registration statement as awards under the plans are exercised and/or vest.

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is filed by the Registrant relating to (i) 19,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) available for issuance under the Company’s Amended and Restated 2014 Equity Incentive Award Plan (the “2014 Plan”) resulting from an increase approved by the Registrant’s stockholders on June 14, 2024, (ii) 6,500,000 shares of Common Stock that may be added to the reserve of the 2014 Plan pursuant to its terms upon forfeiture, expirations and cancellations of awards or repurchase of shares at the original exercise price originally issued under the Company’s 2016 Employment Commencement Incentive Plan and (iii) 3,000,000 shares of Common Stock to be issued pursuant to the Company’s Amended and Restated 2014 Employee Stock Purchase Plan (the “ESPP”) resulting from an increase approved by the Registrant’s stockholders on June 14, 2024.

     

    This Registration Statement on Form S-8 is being filed by the Company for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8 (File Nos. 333-202663, 333-210079, 333-216154, 333-223694, 333-230156, 333-237057, 333-254187, 333-263145 and 333-270314) filed with the Securities and Exchange Commission (the “Commission”) on March 11, 2015, March 10, 2016, February 21, 2017, March 16, 2018, March 8, 2019, March 10, 2020, March 12, 2021, March 1, 2022, March 7, 2023 and February 28, 2024, respectively.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    In this registration statement, Ardelyx, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

     

    Item 3. Incorporation of Documents by Reference.

     

    The SEC allows the Registrant to “incorporate by reference” the information it files with them, which means that the Registrant can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. The Registrant hereby incorporates by reference into this registration statement the following documents previously filed with the SEC:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024 (File No. 001-36485);
       
    (b)

    The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, as filed with the SEC on May 2, 2024, August 1, 2024 and October 31, 2024 respectively; 

     

       
    (c) The Registrant’s Current Reports on Form 8-K filed with the SEC on March 5, 2024, May 23, 2024, June 17, 2024, July 2, 2024, August 12, 2024 and October 9, 2024;

     

     

     

     

    (d) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 29, 2024; and

     

    (e) The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-36485), filed by the Registrant with the SEC under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 9, 2014, as amended by the description of the Registrant’s Common Stock contained in Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 8, 2021, including any amendments or reports filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders, or document or current report furnished under any current or future items of Form 8-K (including current Items 2.02 and 7.01, and exhibits furnished on such form that relate to such items), in each case, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duties of care as directors. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

      ● any breach of the director’s duty of loyalty to us or our stockholders;

     

      ● any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      ● any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

     

      ● any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

     

     

     

     

    As permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws provide that:

     

      ● we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

     

      ● we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

      ● the rights provided in our amended and restated bylaws are not exclusive.

     

    Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. We have also entered into separate indemnification agreements with our directors and officers which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended (the “Securities Act”).

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

            Incorporated by Reference    

    Exhibit

    Number

      Exhibit Description   Form   Date  

    Exhibit

    Number

     

    Filed

    Herewith

    4.1   Amended and Restated Certificate of Incorporation.   8-K   June 24, 2014   3.1    
    4.2   Certificate of Amendment to Amended and Restated Certificate of Incorporation.   8-K   June 20, 2023   3.1    
    4.3   Amended and Restated Bylaws.   8-K   June 24, 2014   3.2    
    4.4   Form of Common Stock Certificate.   S-1/A   June 18, 2014   4.2    
    5.1   Opinion of Latham & Watkins LLP.               X
    23.1   Consent of Independent Registered Public Accounting Firm.               X
    23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).               X
    24.1   Power of Attorney (included on signature page hereto).               X
    99.1(#)   Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan.   8-K   June 17, 2024   10.1    
    99.2(#)   Ardelyx, Inc. Amended and Restated 2014 Employee Stock Purchase Plan.   8-K   June 17, 2024   10.2    
    107.1   Filing Fee Table.               X

     

    #Indicates management contract or compensatory plan.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (1) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (2) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Waltham, Massachusetts, on November 5, 2024.

     

    ARDELYX, INC.  
         
    By: /s/ Michael Raab  
    Name: Michael Raab  
    Title: President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Michael Raab, Justin Renz and Elizabeth Grammer, and each of them, as attorneys-in-fact, each with the power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Michael Raab   President, Chief Executive Officer and
    Director
    (principal executive officer)
      November 5, 2024
    Michael Raab    
             
    /s/ Justin Renz   Chief Financial and Operations Officer
    (principal financial officer)
      November 5, 2024
    Justin Renz    
             
    /s/ Robert Felsch   Chief Accounting Officer
    (principal accounting officer)
      November 5, 2024
    Robert Felsch      
             
    /s/ David Mott   Chairman of the Board of Directors   November 5, 2024
    David Mott    
             
    /s/ Robert Bazemore   Director   November 5, 2024
    Robert Bazemore    
             
    /s/ William Bertrand, Jr.   Director   November 5, 2024
    William Bertrand, Jr.    
             
    /s/ Muna Bhanji   Director   November 5, 2024
    Muna Bhanji, R.Ph        
             
    /s/ Onaiza Cadoret-Manier   Director   November 5, 2024
    Onaiza Cadoret-Manier    
             
    /s/ Richard Rodgers   Director   November 5, 2024
    Richard Rodgers    
         

     

     

     

    Get the next $ARDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Overweight
    Piper Sandler
    9/3/2025$14.00Strong Buy
    Raymond James
    6/18/2025$10.00Buy
    H.C. Wainwright
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Reilly Joseph James was granted 46,200 shares, increasing direct ownership by 42% to 156,781 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    1/27/26 4:13:38 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Kelliher Mike was granted 103,080 shares, increasing direct ownership by 38% to 374,261 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    1/26/26 4:29:59 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Hohenleitner Susan was granted 85,670 shares, increasing direct ownership by 58% to 232,566 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    1/26/26 4:27:51 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Ardelyx with a new price target

    Raymond James resumed coverage of Ardelyx with a rating of Strong Buy and set a new price target of $14.00

    9/3/25 8:26:50 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Ardelyx with a new price target

    H.C. Wainwright resumed coverage of Ardelyx with a rating of Buy and set a new price target of $10.00

    6/18/25 7:56:36 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ARDX
    SEC Filings

    View All

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Receives New Patent for Tenapanor

    WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled "Oral Formulations of Tenapanor" with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products wit

    2/3/26 8:29:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

    WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. ACCEL is a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of tenapanor for the treatment of CIC in adults when administered twice daily for 26 consecutive wee

    1/28/26 8:29:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/18/25 9:28:07 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $737,260 worth of shares (200,000 units at $3.69), increasing direct ownership by 8% to 2,696,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/11/25 9:40:28 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $329,120 worth of shares (100,000 units at $3.29), increasing direct ownership by 4% to 2,496,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    5/19/25 5:02:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.

    SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)

    1/30/26 1:30:22 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ardelyx Inc.

    SCHEDULE 13G - ARDELYX, INC. (0001437402) (Subject)

    1/12/26 4:36:09 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ARDELYX, INC. (0001437402) (Filer)

    1/8/26 8:34:30 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

    WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength

    10/13/25 8:30:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Announces Changes to the Executive Leadership Team

    Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs today announced changes to the Executive Leadership Team. The company announced the appointment of Edward Conner, M.D. to the position of Chief Medical Officer. Dr. Conner is a seasoned biopharmaceutical executive with more than two de

    8/4/25 4:08:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

    WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Officer, and James P. Brady has joined the company as Chief Human Resources Officer. Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief Business Officer, Mr.

    6/2/25 4:05:01 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Financials

    Live finance-specific insights

    View All

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH® Q3 revenue of $27.4 million, up 9% compared to Q2 2025 Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic areas Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet signifi

    10/30/25 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

    WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the I

    10/13/25 8:35:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    7/10/24 6:32:11 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    2/13/24 5:26:59 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care